体外骨形态发生蛋白4抑制乳腺癌细胞的增殖和迁移

目的:研究骨形态发生蛋白4(BMP4)对乳腺癌细胞MCF-7增殖、迁移和侵袭能力的影响.方法:将重组慢病毒Lv-BMP4及干扰慢病毒Lv-shBMP4感染MCF-7细胞,构建MCF-7/Lv-BMP4过表达组及MCF-7/Lv-shBMP4干扰实验组,同时设空白组(Blank)、慢病毒空载对照组(Lv-NC)、 过表达...     

骨形态发生蛋白9抑制人乳腺癌MDA-MB-231细胞体外侵袭和迁移

目的 探讨骨形态发生蛋白9(BMP9)对乳腺癌MDA-MB-231细胞侵袭、迁移能力的影响.方法 RT-PCR法检测MDA-MB-231细胞系中BMP9的表达;扩增高滴度的BMP9表达腺病毒,感染MDA-MB-231细胞,制备高表达BMP9的重组MDA-MB-231/BMP9细胞,以此作为实验组;同时以含GFP的窄载腺病毒感染该细胞为MDA-MB-231/GFP,联合空白MDA-MB-231共同作为对照组;通过平板集落形成实验、细胞划痕实验、Transwell侵袭实验检测重组MDA-MB-231/BMP9细胞侵袭及迁移能力.结果 与对照组细胞相比,实验组细胞中BMP9 mRNA表达水平明显增高;实验组细胞集落形成率由对照的90.6%±2.5%与85.6%±3.5%显著下降至57.3%±4.5%(P＜0.05);实验组划痕愈合率由对照的95.4%±3.1%与92.5%±2.4%下降至74.0%±3.6%(P＜0.05);实验组穿膜细胞数由对照的(255.3±16.1)个与(267.3±14.9)个下降至(150.3±14.6)个(P＜0.05).结论 BMP9可以在体外抑制乳腺癌MDA-MB-231细胞的侵袭与迁移.     

人骨形态发生蛋白2和9对人胃癌MNK-45细胞增殖、凋亡和迁移的影响及其机制

 目的：研究人骨形态发生蛋白2和9（BMP2和BMP9）对人胃癌MNK-45细胞增殖、凋亡和迁移的影响,并初步探讨其作用机制。方法：用重组腺病毒AdBMP2和AdBMP9感染MNK-45细胞,采用MTT法、Hoechst 33258染色、流式细胞术(FCM)、 划痕愈合实验和Transwell小室检测BMP2和BMP9 对MNK-45细胞增殖、凋亡和迁移能力的影响, Western blotting检测总GSK-3β、磷酸化GSK-3β（p-GSK-3β）及β-catenin的表达水平。结果：(1）MTT显示AdBMP2和AdBMP9转染后,MNK-45细胞的增殖自第3 d开始被抑制并呈时间依赖性;(2）Hoechst 33258染色与FCM一致显示上调BMP2和BMP9表达可以促进MNK-45细胞的凋亡;(3） 划痕愈合与Transwell迁移实验结果一致提示上调BMP2和BMP9表达均可抑制MNK-45细胞的迁移;(4）Western blotting显示BMP2组和BMP9组的p-GSK-3β均较GFP组升高,但对β-catenin的表达量无明显影响（P>0.05）;上述结果与对照组相比差异均有统计学意义（P<0.05或P<0.01）。结论：上调BMP2和BMP9表达对MNK-45细胞的增殖具有抑制作用,其机制与β-catenin无明显关系。     

人骨肉瘤细胞株中骨形态发生蛋白-1的检测、克隆和表达

目的:利用基因工程技术生产人骨形态发生蛋白-1的高保守区多肽, 为进一步产生广谱型BMP-1抗体提供有效的抗原蛋白。方法:通过分析BMP-1类各种分子的基因序列及蛋白结构, 选择其中的一个片段作为目的基因。从人骨肉瘤细胞株Saos-2中提取总RNA, 用RT-PCR扩增目的基因片段并克隆到原核表达载体pMALc2中, 构建成重组质粒BMP-1(322-588aa)-pMALc2。将该重组质粒转化大肠杆菌DH5-α, 经过筛选鉴定获得数个阳性克隆, 再进行DNA序列测定。最后用IPTG诱导宿主菌表达融合蛋白。结果:BMP-1基因片段被成功地克隆到pMALc2载体中, 在IPTG的诱导下能高效表达, 融合蛋白的表达量占细菌蛋白总量的(66-72)%。结论:所获得的重组蛋白包含BMP-1的几个完整的重要结构域(2个CUB区和1个EGF区), 为BMP-1类分子所共有的高度保守区。该重组蛋白作为抗原, 可进一步用于产生能有效、特异地识别人类BMP-1类分子的广谱型BMP-1抗体。     

莪术醇抑制人骨肉瘤细胞系的增殖和促凋亡

目的 探究莪术醇对人骨肉瘤细胞系MG-63和U2OS体外增殖、凋亡的影响和作用机制。方法 将MG-63细胞和U2OS细胞分为对照组、莪术醇20、40、80和160μmol/L干预组;MTT法检测MG-63、U2OS细胞增殖;Transwell小室法检测细胞迁移和侵袭;流式细胞测量细胞凋亡;RT-qPCR和Western blot检测凋亡相关蛋白Bax、Bcl2、caspase和β-catenin的mRNA和蛋白表达。结果 莪术醇呈浓度依赖性地抑制MG-63和U2OS细胞增殖,IC₅₀值分别为128.03μmol/L、117.95μmol/L。与对照组相比,莪术醇显著抑制MG-63、U2OS细胞的体外迁移和侵袭(P<0.05),并诱导细胞凋亡(P<0.05)。与对照组相比,莪术醇组促进Bax、caspase 3表达,抑制Bcl2表达(P<0.05),MG-63、U2OS细胞内β-catenin的mRNA表达水平和蛋白表达均被显著抑制(P<0.05)。结论 莪术醇显著抑制人骨肉瘤细胞系MG-63、U2OS增殖,诱导细胞凋亡。     

骨形态发生蛋白7在骨科的应用

背景：骨形态发生蛋白家族因具有独特的异位骨诱导活性而被发现并被命名为骨形态发生蛋白,与胚胎组织的发育、功能维持及组织的修复均密切相关,是诱导骨发生的主要活性因子。骨形态发生蛋白7是骨形态发生蛋白家族中的一员,主要在骨、肾组织中表达,与胚胎组织的发育、功能维持及组织的修复均密切相关。 目的：全面了解骨形态发生蛋白7在骨发育和骨折愈合过程中的表达及作用。 方法：电子检索和计算机Medline数据库1990/2010收录的骨形态发生蛋白相关综述和论文报告,并分析生物学作用及调控途径的研究进展。 结果与结论：随着研究的深入,骨形态发生蛋白7可望在骨折愈合、退行性骨关节炎、相关骨病的防治中发挥重要的作用。骨形态发生蛋白7的生物学活性使其对骨折、骨缺损、延迟愈合,骨不连、骨质疏松等多种骨科疾病的治疗具有巨大的临床应用价值。已有证据表明骨形态发生蛋白局部应用或骨形态发生蛋白涂层有利于假体-骨界面的骨整合,包括假体周围骨缺损的治疗。     

人胚胎长骨中骨形态发生蛋白的免疫组化研究

目的：探讨骨形态发生蛋白与人胚胎骨发生及发育的关系。方法：用免疫组化技术和图像分析系统研究了第9－24周人胚胎股骨中骨形态发生蛋白的分布规律及胎龄性变化。结果：第9周胚胎股骨为软骨锥形,雏形的软骨膜,软骨基质及其两端的软骨细胞骨形态发生蛋白呈阳性反应,第10－24周胚胎股骨中,骨形态发生蛋白阳性反应主要见于成骨细胞,骨膜内层细胞,新生骨细胞及骨基质中,破骨细胞及骨髓细胞骨形态发生蛋白也呈阳性反应,骺软骨为阴性,但其内的软骨管为阳性反应,图象分析测定表明：人胚胎股骨内成骨细胞及骨小梁的平均灰度值随胎龄增加而逐渐下降,同一股骨内不同部位的骨小梁和成骨细胞的平均灰度值有所不同,结论：骨形态发生蛋白与胚胎骨的发生及发育密切相关。     

人骨形态发生蛋白- 4cDNA的克隆和序列测定

骨形态发生蛋白（ｂｏｎｅ　ｍｏｒｐｈｏｇｅｎｅｔｉｃ　ｐｒｏｔｅｉｎ，ＢＭＰ）是由Ｕｒｉｓｔ［１］在１９６５年对脱钙骨基质的成骨研究中发现的。他们将脱钙骨基质移植于动物的皮下和肌肉内，可诱导软骨化骨，随后从骨中分离出了一种小分子的糖蛋白，这种糖蛋白可诱导异位宿主区间充质细胞向成骨和成软骨细胞的方向分化。ＢＭＰ在组织中含量甚微，每１　０００　ｇ皮质骨仅含１～２　μｇ［２］，因而利用基因工程生产重组ＢＭＰ成为必须。赵明［４］、崔有宏［５］和刘礼初［６］均在大肠杆菌中表达有活性的ＢＭＰ，但多为人ＢＭＰ…     

骨形态发生蛋白-7及其受体的信号转导

骨形态发生蛋白-7(BMP-7)是BMP家族中的一员,具有高效的骨诱导活性,属于转化生长因子-β(TGF-β)超家族成员。BMP-7受体属于转化生长因子β(TGF-β)受体超家族的成员,是一种膜蛋白受体。BMP-7首先与Ⅱ型跨膜丝/苏氨酸激酶受体(ActRⅡ、ⅡB)结合,受体的蛋白激酶活性被激活,再与Ⅰ型受体(主要是ALK2)结合,形成异源二聚体,催化Ⅰ型受体GS区的丝氨酸和苏氨酸残基磷酸化。Ⅰ型受体被激活后,作用于Smad1、Smad5或Smad8的C端SSXS模体,使其磷酸化,再与Smad4形成复合物,进入核内与多种转录因子相互作用发挥基因调控作用。     

高同型半胱氨酸诱导人成骨肉瘤MG63细胞损伤的机制

目的 探讨高同型半胱氨酸(HHcy)诱导人成骨肉瘤MG63细胞损伤的分子机制.方法 体外培养的人成骨肉瘤MG63细胞经不同浓度(0.001mol/L、0.003mol/L和0.005mol/L)的Hcy处理不同时间后,采用2',7'-二氯二氢荧光素二乙酸盐(H2DCFDA)探针在荧光分光光度计下检测细胞内活性氧(ROS...     

乳酸链球菌素诱导氧化应激促进人骨肉瘤MG63细胞凋亡

目的:探讨乳酸链球菌素(nisin)对人骨肉瘤MG63细胞凋亡及其相关的氧化应激机制.方法:乳酸链球菌素单独或联合抗氧化剂N-乙酰-L-半胱氨酸(N-acetyl-L-cysteine,NAC)处理MG63细胞后,采用CCK-8法检测细胞活力;annexin-V/PI双染法检测细胞凋亡;2',7'-二氯荧光素二乙酸酯(...     

Noggin蛋白对人骨肉瘤细胞MG63增殖性的影响

目的研究外源性Noggin蛋白对骨肉瘤细胞MG63增殖活性的影响及其分子机制。方法用不同浓度的Noggin蛋白（A组为对照组;B、C、D组浓度分别为：1、10、201μg／m1）作用于MG63细胞,利用倒置显微镜观察细胞生长和形态变化情况：MTT比色法检测Noggin蛋白对MG63细胞增殖活性的影响及其与剂量和时间的关系。结果倒置显微镜下观察及MTT法检测均证实,外源性Noggin蛋白对MG63细胞的增殖有抑制作用,浓度越高作用越强,并且存在明显的时间依赖性。结论Noggin蛋白可以明显抑制骨肉瘤细胞的增殖,并呈剂量和时间依赖性。     

Si(3)N(4)-bioglass composites stimulate the proliferation of MG63 osteoblast-like cells and support the osteogenic differentiation of human bone marrow cells

The in vitro osteocompatibility of a novel Si₃N₄-bioglass composite (70–30% weight proportion) with improved mechanical properties (fracture TOUGHNESS=4.4 MPa m^1/2; bending STRENGTH=383±47 MPa) is reported. Immersion of the composite samples in culture medium (30 min to 7 days) resulted in rapid protein adsorption to the surface and, also, dissolution of the intergranular phase of bioglass (time-dependent process) with the formation of different size cavities. “As-received” and pre-treated material samples presented a similar behaviour concerning the proliferation of MG63 osteoblast-like cells, evaluated during a 5-day culture period. Seeded materials showed a higher cell growth rate as compared to cultures performed on the standard plastic culture plates. To assess the osteogenic potential of the composite, “as-received” material samples were seeded with human bone marrow cells and cultured for 35 days in experimental conditions that favour the development of the osteoblastic phenotype. The cell adhesion process was similar to that observed in control cultures. Cells successfully adapted to the irregularities of the surface and were able to grow towards inside the cavities; in addition, osteogenic differentiation occurred with the formation of abundant cell-mediated mineralised deposits. Results suggest that this Si₃N₄-bioglass composite seems to be a promising candidate for high-stress medical applications.     

Effects of N-acetylcysteine on TEGDMA- and HEMA-induced suppression of osteogenic differentiation of human osteosarcoma MG63 cells

Triethyleneglycol dimethacrylate (TEGDMA) and 2-hydroxyethyl methacrylate (HEMA) are major resinous components of dental restorative materials and dentin bonding adhesives. Resin monomers are known to cause cytotoxicity in mammalian cells via oxidative stress and inhibit differentiation of dental pulp cells and osteoblasts. This study was aimed to investigate whether oxidative stress was involved in the inhibition of TEGDMA- and HEMA-induced differentiation. TEGDMA and HEMA reduced alkaline phosphatase (ALP) activity and the mRNA expression of the osteopontin (OPN) gene in MG63 cells at noncytotoxic concentrations. On the other hand, N-acetylcysteine (NAC) did not affect ALP activity at concentrations below 10 mM. Reduced ALP activity and OPN mRNA expression by TEGDMA were partially recovered via cotreatment with NAC. However, NAC did not exhibit significant effects in HEMA-treated cells. Glutathione (GSH) levels were also down-regulated by both TEGDMA and HEMA. The addition of NAC induced the partial recovery of GSH in cells treated with 0.5 mM TEGDMA. On the other hand, the levels of GSH in HEMA-treated cells were not affected by NAC. These results suggest that oxidative stress is involved in the suppression of differentiation by TEGDMA. Translocation of Nrf2 from the cytoplasm to the nucleus has been known to play a role in the suppression of osteogenic differentiation by oxidative stress. However, Nrf2 did not move into the nucleus in resin monomer-treated MG63 cells, suggesting the contribution of other signaling pathways to the suppressive effects of resin monomers.     

MG63和MG63/ADR骨肉瘤裸鼠模型血管内皮生长因子和核因子κB1的表达

背景：恶性肿瘤耐药研究中发现核因子κB1及血管内皮生长因子基因可能与肿瘤耐药密切相关。 目的：观察MG63和MG63/ADR骨肉瘤裸鼠模型中血管内皮生长因子和核因子κB1表达的差异。 方法：对数期生长的MG63细胞采用阿霉素浓度递增培养法冲击诱导建立MG63/ADR细胞株。BALB/C裸鼠随机分为2组,分别将含5.0×106个MG63和MG63/ADR细胞的0.2 mL细胞悬液采用皮下接种法注入裸鼠的一侧腋部皮下。第6周处死裸鼠取材。 结果与结论：注射MG63和MG63/ADR细胞的2组裸鼠成瘤率均为100%;免疫组织化学及RT-PCR方法检测发现MG63/ADR组瘤灶中血管内皮生长因子和核因子κB1基因和蛋白的表达均明显高于MG63组(P < 0.05)。说明血管内皮生长因子和核因子κB1表达的上调可能是导致骨肉瘤耐药的重要原因。     

Nanocrystalline diamond: In vitro biocompatibility assessment by MG63 and human bone marrow cells cultures

Nanocrystalline diamond (NCD) has a great potential for prosthetic implants coating. Nevertheless, its biocompatibility still has to be better understood. To do so, we employed several materials characterization techniques (SEM, AFM, micro-Raman spectroscopy) and cell culture assays using MG63 osteoblast-like and human bone marrow cells. Biochemical routines (MTT assays, Lowry's method, ALP activity) supported by SEM and confocal microscopy characterization were carried out. We used silicon nitride (Si3N4) substrates for NCD coatings based on a previous demonstration of the superior adhesion and tribological performance of these NCD coated ceramics. Results demonstrate an improved human osteoblast proliferation and the stimulation of differentiated markers, like ALP activity and matrix mineralization, compared with standard polystyrene tissue culture plates. The nanometric featuring of NCD, associated to its chemical affinity are key points for bone regeneration purposes.     

转化生长因子β3和骨形态发生蛋白2基因共转染骨髓干细胞

背景：骨形态发生蛋白2及转化生长因子β是骨再生中重要的因子,提高其表达可促进骨髓间充质干细胞的成骨分化。 目的：构建携带转化生长因子β3和骨形态发生蛋白2基因的慢病毒载体,观察其在骨髓间充质干细胞中的表达情况。 方法：应用重组慢病毒技术构建同时携带转化生长因子β3、骨形态发生蛋白2和绿色荧光蛋白基因的重组慢病毒表达载体,并用其转染体外培养的第3代兔骨髓间充质干细胞,以转染携带转化生长因子β3或骨形态发生蛋白2单一基因的慢病毒或单独慢病毒的骨髓间充质干细胞作为对照。转染后1周分别提取各组细胞的总RNA和蛋白进行检测。 结果与结论：荧光显微镜下见转染转化生长因子β3和(或)骨形态发生蛋白2基因3 d的骨髓间充质干细胞发绿色荧光,转染效率达90%以上。RT-PCR和Western blot结果显示,转染转化生长因子β3和骨形态发生蛋白2基因的骨髓间充质干细胞转化生长因子β3和骨形态发生蛋白2 mRNA和蛋白的表达均高于单一基因转染组及空白对照组。可见应用慢病毒可成功将转化生长因子β3和骨形态发生蛋白2基因转染至骨髓间充质干细胞并实现其高效表达,且两种基因具有协同促表达作用。     

Expression of CD31, Met/hepatocyte growth factor receptor and bone morphogenetic protein in bone metastasis of osteosarcoma

The mechanism of metastasis of osteosarcoma cells to other bones has not yet fully been clarified. The purpose of the present study was to examine whether various factors involve the formation of osteosarcoma metastatic foci in other bones. Immunohistochemically, CD31 expression in osteosarcoma with no bone metastasis and osteosarcoma with bone metastasis was noted in 10 and 75% of cases, respectively. Met/hepatocyte growth factor (HGF) receptor expression in osteosarcoma with no bone metastasis and osteosarcoma with bone metastasis was noted in 90 and 25% of cases, respectively. Bone morphogenetic protein (BMP) expression in osteosarcoma with no bone metastasis and osteosarcoma with bone metastasis was noted in 20 and 75% of cases, respectively. Metastasis of osteosarcoma cells to other bones was significantly correlated with expression of BMP and CD31 and with no expression of Met/HGF receptor protein in osteosarcoma cells. In contrast, expression of insulin-like growth factor receptor in osteosarcoma cells did not correlate significantly with bone metastasis. These results suggest that formation of metastatic foci of osteosarcoma cells in other bones is regulated by CD31, which is associated with migration between endothelial cells, by BMP, which can induce and activate various mesenchymal cells affecting bone formation, and by escape of effect by HGF, which promotes differentiation of osteosarcoma cells.     

2-甲氧基雌二醇对骨肉瘤MG63细胞增殖和凋亡的影响及其机制研究

目的探讨2-甲氧基雌二醇(2-methoxyestradiol,2-ME)对骨肉瘤MG63细胞增殖和凋亡的影响及其分子机制。方法不同浓度(0、10、20、40μmol/L)的2-ME作用于肿瘤细胞后,通过显微镜观察细胞形态变化、MTT实验检测增殖抑制、流式细胞术检测细胞周期和凋亡、Western Blot和qRT-PCR实验检测相关分子表达情况。结果随着2-ME浓度的增加,细胞形态学观察显示肿瘤细胞数量逐渐减少、变形;MTT实验表明2-ME对肿瘤细胞增殖抑制作用逐渐增强;流式细胞术结果显示,2-ME能剂量依赖性的诱导肿瘤细胞凋亡,使肿瘤细胞周期阻滞在G_0/G_1期;Western Blot和qRT-PCR实验结果表明,细胞内Bcl-2、VEGF的表达逐渐下降,而Caspase-3的表达则逐渐升高。结论2-ME能抑制骨肉瘤MG63细胞增殖、诱导凋亡,其作用机制可能与Bcl-2、VEGF、Caspase-3相关。